Compare LOVE & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOVE | NVCT |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.2M | 220.0M |
| IPO Year | 2018 | 2021 |
| Metric | LOVE | NVCT |
|---|---|---|
| Price | $14.04 | $7.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $27.60 | $13.50 |
| AVG Volume (30 Days) | ★ 328.4K | 52.4K |
| Earning Date | 03-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $680,628,000.00 | N/A |
| Revenue This Year | $7.65 | N/A |
| Revenue Next Year | $8.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.33 | $5.55 |
| 52 Week High | $21.90 | $11.52 |
| Indicator | LOVE | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 65.93 | 30.16 |
| Support Level | $14.04 | $7.23 |
| Resistance Level | $15.26 | $8.46 |
| Average True Range (ATR) | 0.74 | 0.40 |
| MACD | 0.43 | -0.16 |
| Stochastic Oscillator | 90.75 | 11.67 |
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.